RETATRUTIDE
Retatrutide is an experimental injectable medication developed by Eli Lilly that acts as a triple agonist of the GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. Unlike earlier agents such as Semaglutide (GLP-1 agonist only) or Tirzepatide (dual GLP-1/GIP agonist), retatrutide adds the glucagon receptor pathway, which may further boost energy expenditure and fat oxidation while preserving the appetite suppression and glycemic benefits of its predecessors. By stimulating these three metabolic pathways simultaneously, it aims to improve blood sugar control, enhance satiety, increase energy expenditure, and promote significant weight loss in people with obesity or type 2 diabetes. Early clinical trial results suggest that retatrutide may lead to greater reductions in body weight and improvements in cardiometabolic health compared to current GLP-1/GIP dual agonists, positioning it as a promising next-generation therapy in the field of metabolic disease management.
Starting Dose:
10mg vial reconstituted in 3 ml Bacteriostatic Water
Low Baseline Bodyfat - 0.3mg
0.1ml (10 units) / week
High Baseline Bodyfat - 2mg
0.6ml (60 units) / week
OR
20 units - 3 times / week
KLOW
The Blend: BPC-157 + TB-500 + GHK-Cu + KPV
This four-peptide blend is designed to target the entire healing and repair cycle from multiple angles. Each component operates through different molecular pathways, but together they reinforce and amplify one another’s effects.
Together, these peptides form a synergistic regenerative platform that goes beyond simple wound repair. They have shown potential in:
Acute injuries: muscle tears, ligament sprains, tendon ruptures, surgical recovery
Chronic damage: inflammatory gut disorders, arthritis, cardiovascular decline, neuroinflammation
Anti-aging support: slowing loss of regenerative capacity, reducing oxidative stress, and mitigating fibrosis and vascular stiffening
Scar reduction and tissue quality: BPC-157 and TB-500 build structural integrity, GHK-Cu improves collagen organization, and KPV prevents hypertrophic scar formation
System-wide resilience: protection of gut lining, nerves, skin, cardiovascular system, and cognitive function through improved cellular signaling and repair balance
This makes the blend highly versatile—a “multi-tool” for regeneration—because it not only speeds healing but ensures tissues heal in a more functional and long-lasting way.
GHK-Cu
Structure & Origin: A naturally occurring tripeptide (glycyl-histidyl-lysine) bound to copper, first identified in human plasma.
Mechanisms: Stimulates collagen and glycosaminoglycan synthesis, promotes fibroblast growth, activates metalloproteinases to remodel damaged tissue, enhances antioxidant defenses, and scavenges free radicals. Regulates activity of ~30% of human genes, balancing tissue repair with controlled protein breakdown.
Effects: Improves skin and connective tissue integrity, supports wound healing, reduces oxidative stress and inflammation, and contributes anti-aging benefits by improving DNA repair, reducing amyloid aggregation, and balancing copper metabolism. Enhances tissue quality and collagen organization during repair.
BPC-157
Structure & Origin: Synthetic 15–amino acid peptide derived from Body Protective Compound in gastric juice.
Mechanisms: Enhances nitric oxide (NO) signaling, promotes angiogenesis, alters gene expression controlling immune and vascular responses, and upregulates GH receptors on fibroblasts for targeted repair. Rapid absorption and wide tissue distribution.
Effects: Strongly promotes regeneration of ligaments, muscles, tendons, nerves, gut, and organs. Accelerates wound closure, improves mobility and durability of healed tissue, protects against NSAID-induced gastric damage, and restores balance in chronic inflammatory states. Enhances blood vessel growth and tissue repair efficiency.
TB-500
Structure & Origin: Synthetic peptide based on TB-4, a natural actin-binding protein.
Mechanisms: Binds actin to improve cellular motility, modulates gene expression beyond structural roles, regulates angiogenesis, and influences pathways such as TGF-β to reduce fibrosis.
Effects: Enhances cell movement, reduces fibrosis, accelerates wound healing, supports muscle regeneration and stem cell activation, promotes collagen deposition, reduces scar formation, and supports cardiac recovery. Also downregulates inflammatory cytokines like TNF-α and IL-1.
KPV
Structure & Origin: Tripeptide (Lys-Pro-Val) from the C-terminal of α-Melanocyte-Stimulating Hormone (α-MSH).
Mechanisms: Inhibits NF-κB signaling, suppresses pro-inflammatory cytokines (TNF-α, IL-8), reduces immune cell infiltration, and enhances antioxidant enzyme activity. Works independently of α-MSH receptor binding.
Effects: Temper excessive inflammation without impairing normal wound healing, reduces pain and scarring, prevents hypertrophic scar formation and fibrosis, and selectively targets pathological inflammation. Exhibits antimicrobial effects (anti-Staphylococcus, anti-Candida). Supports lung and cardiovascular health by reducing inflammatory scarring and vascular stiffening.
Recommended Dose:
80mg vial reconstituted in 3 ml Bacteriostatic Water
GHK-Cu 50mg + BPC-157 10mg + TB-500 10mg + KPV 10mg
Starting dose - 1.6:0.3:0.3:0.3 mg /day
0.1ml (10 units) / day
Alternative dose - 5:1:1:1 mg / day
0.3ml (30 units) / day
Titrate as needed
Dosing for individual components coming soon